Questions are mounting over AstraZeneca vaccine after it said a lower dosage level that appeared more effective resulted from a manufacturing discrepancy.
The comments came after AstraZeneca & Oxford University acknowledged a manufacturing error that is raising doubts about preliminary results of their experimental Covid-19 vaccine.
While AstraZeneca earlier showed 70% efficacy on average in a late-stage study, the scant details released by the UK partners raises doubts on whether US regulators will clear it.
The vaccine was 90% effective when a half-dose was given before a full-dose booster. However, that regime was administered to participants in a group whose age was capped at 55.
As findings of Astra-Oxford's Covid vaccine early trial results don't seem straightforward, questions are being raised if people will get vaccines with differing upfront efficacy.
AstraZeneca and Oxford are taking a different vaccine approach from the one used by Pfizer and Moderna. Here's what the results could mean in the battle.
If final-stage trial data show AstraZeneca’s candidate gives effective protection, Serum Institute of India may get emergency authorization by December.
The UK drugmaker said the group of patients taking the cancer drug Calquence in addition to standard care didn’t show fewer deaths or respiratory failures.
Concerns about AstraZeneca’s timeline arose this week with UK saying only 4 million doses of the Oxford-Astra shot would be available by the end of the year.
The Army has plans for a technology thrust in the near term, including the use of AI to support decision-making. While well-intentioned, this may have unintended consequences.
COMMENTS